Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CTLA-4/PD-1 expressing MUC1-CAR-T in advanced solid tumors
NCT03179007Phase 2Unknown
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-CTLA-4/PD-1 expressing MUC1-CAR-T in solid tumor. Primary endpoint: Safety of infusion of autologous CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells at 2 years. Status: unknown.
02
Drugs
Anti-CTLA-4/PD-1 expressing MUC1-CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03179007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179007.